You are here: Industry Insights > Avifavir

News List

ChemRar’s Avifavir demonstrates effectiveness against SARS-CoV-2 variants Pharmaceutical-Technology
December 29, 2021
Russia-based ChemRar Group has reported that its drug, Avifavir (favipiravir), demonstrated effectiveness against several SARS-CoV-2 variants, including Delta and Omicron.
ChemRar Group announces the Russian Avifavir® drug is effective against variants of COVID-19, including Delta and Omicron prnasia
December 28, 2021
ChemRar Group announces the Russian Avifavir® (INN: favipiravir) drug is effective against various variants of SARS-CoV-2 (coronavirus), including Delta and Omicron, as it affects the highly conservative...
Viriom, Chromis’ Avifavir reduces time to virus elimination in Covid-19 patients pharmaceutical-technology
March 10, 2021
Viriom and Chromis have reported that data from a study of directly acting antiviral drug, Avifavir (favipiravir) demonstrated reduced time to virus elimination in Covid-19 patients.
RDIF and ChemRar agree to supply Avifavir to 17 countries pharmaceutical-technology
September 27, 2020
The Russian Direct Investment Fund (RDIF) and ChemRar Group will be supplying a Covid-19 drug, Avifavir, to 17 countries.
Russia’s RDIF, ChemRar to boost production of Avifavir for Covid-19 pharmaceutical-technology
July 06, 2020
A joint venture established by the Russian Direct Investment Fund (RDIF) and ChemRar Group is set to boost production of Avifavir, which secured temporary approval from the Russian government to treat Covid-19.
60,000 doses of avifavir, a COVID-19 treatment, to be delivered in June europeanpharmaceuticalreview
June 02, 2020
The Russian Direct Investment Fund (RDIF) and the ChemRar Group are to deliver the doses of avifavir, approved in Russia as a COVID-19 therapeutic, to Russian hospitals.
Russia grants temporary approval for Avifavir to treat Covid-19 pharmaceutical-technology
June 02, 2020
The Ministry of Health of the Russian Federation has granted a temporary registration certificate to Covid-19 treatment, Avifavir, produced by the Russian Direct Investment Fund (RDIF) and ChemRar Group.